WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Similar documents
THIS IS NOT YOUR GRANDMOTHER S DISEASE: WHAT DOES BEING DIAGNOSED WITH PARKINSON S DISEASE MEAN TODAY?

Communicating About OFF Episodes With Your Doctor

Treatment of Parkinson s Disease: Present and Future

Optimizing Clinical Communication in Parkinson s Disease:

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

PD: Key Treatment Considerations

Evaluation and Management of Parkinson s Disease in the Older Patient

Parkinson s Disease Update

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

10th Medicine Review Course st July Prakash Kumar

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Welcome and Introductions

Deep Brain Stimulation: Indications and Ethical Applications

Key Concepts and Issues in Parkinson s Disease in 2016

Medication Management & Strategies When the levodopa honeymoon is over

Surgical Management of Parkinson s Disease

Welcome and Introductions

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Parkinson s Disease Current Treatment Options

Best Medical Treatments for Parkinson s disease

SPOTLIGHT ON MOVEMENT FUNCTION: COPING WITH ON/OFF PERIODS WELCOME AND INTRODUCTIONS

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Parkinson's Disease KP Update

Parkinson s Disease. Gillian Sare

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Update on Parkinson s disease and other Movement Disorders October 2018

Dr Barry Snow. Neurologist Auckland District Health Board

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Deep Brain Stimulation for Parkinson s Disease & Essential Tremor

EMERGING TREATMENTS FOR PARKINSON S DISEASE

Clinical Features and Treatment of Parkinson s Disease

Update in the Management of Parkinson s Disease

Faculty. Joseph Friedman, MD

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Medications used to treat Parkinson s disease

Punit Agrawal, DO Clinical Assistant Professor of Neurology Division of Movement Disorders OSU Department of Neurology

What s new for diagnosing and treating Parkinson s Disease?

Deep Brain Stimulation: Patient selection

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Parkinson s Disease. Sirilak yimcharoen

What is Parkinson s Disease?

Welcome and Introductions

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

With Time, The Pathology of PD Spreads Throughout the Brain

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

Evidence compendium. Research study summaries supporting the use of Medtronic deep brain stimulation (DBS) for Parkinson s disease

The Shaking Palsy of 1817

Evaluation of Parkinson s Patients and Primary Care Providers

Update on the Treatment of Parkinson s Disease. Neurotherapeutics for Rehab Professionals November 6 th, 2015

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parts of the motor circuits

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S MEDICATION

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

Motor Fluctuations in Parkinson s Disease

Understanding Parkinson s Disease Important information for you and your loved ones

8/28/2017. Behind the Scenes of Parkinson s Disease

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

Surgical Treatment for Movement Disorders

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Indications. DBS for Tremor. What is the PSA? 6/08/2014. Tremor. 1. Tremor. 2. Gait freezing/postural instability. 3. Motor fluctuations

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

The Latest Research in Parkinson s Disease. Lawrence Elmer, MD, PhD Professor, Dept. of Neurology University of Toledo

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Continuous dopaminergic stimulation

See Policy CPT/HCPCS CODE section below for any prior authorization requirements

Deep Brain Stimulation. Is It Right for You?

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Issues for Patient Discussion

Surgical Treatment: Patient Edition

Parkinson s Disease and Treatment Options for the Younger Adult

BORDEAUX MDS WINTER SCHOOL FOR YOUNG

Parkinson s Disease and Treatment Options for the Younger Adult

Deep Brain Stimulation Surgery for Parkinson s Disease

Parkinson s disease. Quick reference guide. Issue date: June Diagnosis and management in primary and secondary care

Canadian Guidelines on Parkinson s Disease Executive Summary

Drugs Affecting the Central Nervous System

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

Margo J Nell Dept Pharmacology

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Prior Authorization with Quantity Limit Program Summary

Commonly encountered medications and their side effects - what the generalist needs to know

Non-Motor Symptoms of Parkinson s Disease

Pharmacological treatment of Parkinson's disease

Scottish Medicines Consortium

Multiple choice questions: ANSWERS

III./3.1. Movement disorders with akinetic rigid symptoms

Section 1: What is Parkinson s? Parkinson's Disease Webinar 4/27/2012. April 27th, :00-1:00 PM EST

PARKINSON S SYMPTOM TRACKER

Transcription:

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

YOUNG ONSET PARKINSON S DISEASE Definition: Parkinson s disease diagnosed before the age of 50 Concerns: Disclosure Employment Family Importance of exercise Specific clinical features

APDA RESOURCES - A CLOSER LOOK BLOG

APDA RESOURCES - WEBINARS

APDA RESOURCES MEDICAL INFORMATION

EXERCISE

CDC GUIDELINES FOR PHYSICAL ACTIVITY FOR ADULTS Adults should move more and sit less throughout the day. Adults should do at least 150 minutes (2 hours and 30 minutes) to 300 minutes (5 hours) a week of moderateintensity, or 75 minutes (1 hour and 15 minutes) to 150 minutes (2 hours and 30 minutes) a week of vigorousintensity aerobic physical activity, or an equivalent combination of moderate- and vigorous-intensity aerobic activity. More beyond this is better Muscle-strengthening activities that involve all major muscle groups on 2 or more days a week are recommended

WHY DOES EXERCISE HELP PD? Exercise increases the number of dopamine receptors in the brain Exercise increases blood flow to the brain Exercise increases nerve growth factors that allow nerves to live longer Exercise increases neuroplasticity the ability for nerve cells to make new connections

NEUROPLASTICITY NEUROPLASTICITY Making new nerve connections

EXERCISE AND PARKINSON S DISEASE Patients were assigned to one of three exercise groups: High intensity treadmill use Low intensity treadmill use Stretching and resistance exercises Findings Walking speed improved in low intensity treadmill group Gait and mobility improved in low and high intensity treadmill group Muscle strength improved in stretching and resistance group Conclusion: combine workout types! The more the better! JAMA Neurol. 2013 Feb;70(2):183-90

EXERCISE IN PD Evidence supports the following claims (Neurology. 2011;77(3):288-94): Cardiovascular fitness is associated with better cognitive and motor scores in PD Longevity in PD is associated with increased physical activity Non motor features of PD such as constipation, fatigue, depression, all improve with exercise and fitness

EXERCISE AND PARKINSON S DISEASE J Hum Kinet. 2016 Sep 1; 52: 35 51. Learn a new motor skill!

WHAT IS THE BEST TYPE OF EXERCISE FOR PD? Vary your workouts Try both skilled exercise, aerobic exercise, resistance training Learn a new motor skill!

SPECIFIC CLINICAL FEATURES OF YOPD

CLINICAL FEATURES OF YOPD Prevalence Feature Presence of family history YOPD vs LOPD YOPD represents about 10% of PD cases More common in YOPD

NON MOTOR FEATURES OF YOPD Symptom Cognitive difficulty Psychosis Autonomic symptoms Sleep disorders Depression Impulse control disorders YOPD vs LOPD YOPD < LOPD YOPD < LOPD YOPD < LOPD YOPD < LOPD YOPD > LOPD YOPD > LOPD Parkinsonism Relat Disord. 2014 May;20(5):530-4 Neurology. 2016 Apr 12;86(15):1400-1407 Int J Neurosci. 2016;126(3):227-34 Can J Neurol Sci. 2016 Jan;43(1):113-9 J Neurol Sci. 2016 Sep 15;368:150-4 Clin Neurol Neurosurg. 2013 Oct;115(10):2103-7

RATE OF PROGRESSION Feature Rate of progression Survival YOPD vs LOPD YOPD < LOPD YOPD > LOPD

MOTOR FEATURES OF YOPD Symptom Severity of symptoms at diagnosis Dystonia YOPD vs LOPD YOPD < LOPD YOPD > LOPD Levodopa induced dyskinesias Motor fluctuations YOPD > LOPD YOPD > LOPD Parkinsonism Relat Disord. 2014 May;20(5):530-4 Neurology. 2016 Apr 12;86(15):1400-1407 Int J Neurosci. 2016;126(3):227-34 Can J Neurol Sci. 2016 Jan;43(1):113-9 J Neurol Sci. 2016 Sep 15;368:150-4 Clin Neurol Neurosurg. 2013 Oct;115(10):2103-7 Mov Disord. 2011 Feb 15;26(3):457-63

MOTOR FLUCTUATIONS IN PARKINSON S DISEASE Clinical response A clinical phenomenon that some patients with Parkinson s disease experience, in which Parkinson s medication works at certain times of the day and does not work at other times. ON ON OFF dose dose time

Clinical response DYSKINESIAS IN PARKINSON S DISEASE dyskinesias ON ON OFF dose time dose

THE GENERAL STRATEGY FOR TREATING OFF TIME Do not let the levels of dopamine fall below a certain level.

Clinical response CURRENT SOLUTIONS TO ON/OFF TIME Making drug delivery more continuous Rescue strategies ON ON dose OFF dose time dose dose dose dose

dose CURRENT SOLUTIONS TO OFF TIME: CONTINUOUS Smooth out Levodopa dosage by giving smaller doses more frequently Add MAOI (e.g. selegiline, rasagiline, safinamide) Add dopamine agonist, including long acting versions (e.g. pramipexole ER, ropinirole XL, rotigotine patch) Add COMT inhibitor (e.g. entacapone, tolcapone) Use longer acting Levodopa formulation: rytary Use longer acting Levodopa formulation: duopa Deep brain stimulation

DEEP BRAIN STIMULATION Subthalamic nucleus (STN) Globus pallidus interna (GPi) Thalamus (Tremor - Vim)

ON TIME WITHOUT DYSKINESIAS IMPROVES FROM 27% TO 74% OF THE WAKING DAY AFTER DBS N Eng J Med. 2001;345:956-63. 27% 19% 49% 23% 7% 74%* Before Surgery(n=96) OFF ON without Dyskinesia ON with Dyskinesia 6 Months After Surgery Bilateral STN Implant (n=91)

CURRENT SOLUTIONS TO OFF TIME: RESCUE Parcopa Apomorphine injections Levodopa inhalation powder dose dose dose

FUTURE SOLUTIONS TO MOTOR FLUCTUATIONS Focused ultrasound Sublingual apomorphine film

FOCUSED ULTRASOUND Focused beams of ultrasound energy converge within the brain tissue to form a small lesion that interferes with the brain circuitry clinicaltrials.gov/ct2/show/nct03319485, clinicaltrials.gov/ct2/show/nct02246374 https://www.insightec.com/

APOMORPHINE SUBLINGUAL FILM Apomorphine sublingual film for rescue dose In February 2019, the FDA did not approve the medication and asked for additional information

YOUNG ONSET PARKINSON S DISEASE Unique concerns: Disclosure, Employment, Family Stay tuned to the upcoming presentations Check out APDA website Importance of exercise Mix up work-out routines high intensity exercise, resistance training Consider learning a skilled motor activity Specific clinical feature Non-motor features tend to be different in YOPD vs LOPD YOPD have more motor fluctuations and dyskinesias

THANK YOU! 1-800-223-2732 apdaparkinson.org

MOTOR FEATURES OF PARKINSON S DISEASE T Tremor R Rigidity A Akinesia or Bradykinesia P Postural instability

NON MOTOR FEATURES OF PARKINSON S DISEASE Motor symptoms Non motor symptoms NEUROPSYCHIATRIC Depression Sleep disorders Cognitive impairment and dementia Apathy SENSORY Visual Loss of smell Pain AUTONOMIC & VISCERAL Orthostatic hypotension Constipation Urinary dysfunction Sexual dysfunction

MOTOR SYMPTOMS ARE CAUSED BY LOSS OF NERVES THAT PRODUCE DOPAMINE control Parkinson s disease

THE LEWY BODY Alpha-synuclein: Abnormal accumulation in Lewy bodies is harmful to nerve cells

MEDICATION EFFICACY AND THE GI TRACT Delayed gastric emptying is a non motor symptom of Parkinson s disease and can interfere with Levodopa absorption Dietary protein can interfere with absorption of Levodopa Other GI pathology may interfere with Levodopa absorption (Helicobacter pylori, Small intestinal bacterial overgrowth (SIBO))

WHAT IF I KNOW THAT MY RESPONSE TO MEDICATION VARIES DURING THE DAY, BUT IT SEEMS RANDOM AND UNRELATED TO MEDICATION DOSES? Very common for patients to feel this way! Keep a medication diary Erratic medication responses Dose failures when a dose is ingested but fails to work Delayed ON when a dose takes longer to work than usual Sudden or unpredictable OFF when medication efficacy ceases suddenly or unpredictably